Agios Pharmaceuticals Inc (STU:8AP)
€ 42 2.6 (6.6%) Market Cap: 2.40 Bil Enterprise Value: 1.90 Bil PE Ratio: 0 PB Ratio: 3.45 GF Score: 41/100

Agios Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / 03:30PM GMT
Release Date Price: €21.2 (-2.75%)
Tessa Romero J.P. Morgan;Analyst

Welcome everyone to the 42nd Annual JPMorgan Healthcare Conference. My name is Tessa Romero, and I am one of the biotech senior analysts here at JPMorgan. Our next presenting company is Agios. And speaking, on behalf of the Company, we have CEO, Brian Gast. Brian, over to you.

Brian Goff Agios Pharmaceuticals
Inc. - CEO

All right. Well, thank you very much tests, and good morning, everybody. I'm really delighted to be here. I'm going to start with introductions on who is with me. We have Cecilia Jones, our CFO, Sarah humans, who is our CMO and Chief Medical Officer. Sorry, Chief Medical Officer and Head of R&D, and also Satya Nadella Nova, who is our Chief Commercial Officer.

So before I get started, I just want to remind everybody that I will be making forward-looking statements that include our expectations and beliefs going forward. And so I would refer you to our SEC filings.

Now our geos is entirely dedicated to developing and delivering transformative therapies for patients who are living

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot